A year and a half since the onset of the COVID-19 pandemic, the global economy is poised to stage its most robust post-recession recovery in 2021. The pharmaceutical industry, which has been at the forefront of the fight against the pandemic, is expected to drive this economic rebound.
The Government of Mauritius is emphasizing the development of a pharmaceutical and vaccine manufacturing industry to integrate biotechnology related R&D into the fabric of the Mauritian economy and diversify the manufacturing base towards such higher value activities.
To this end, a provision of MUR 1 billion (USD 25 million) has been made in the 2021-2022 National Budget for the setting up of the Mauritius Institute of Biotechnology. This Institute will partner with renowned pharmaceutical and biotechnology companies for the manufacturing of COVID-19 and other vaccines and/or other pharmaceutical products in Mauritius.
In this context, the Economic Development Board is inviting local or international companies, with relevant experience in the field to express their interests in implementing pharmaceutical and vaccine manufacturing projects in Mauritius.
To access the full document, please click here